Literature DB >> 6830692

Central nervous system toxicity of interferon.

A Z Rohatiner, P F Prior, A C Burton, A T Smith, F R Balkwill, T A Lister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6830692      PMCID： PMC2011317          DOI： 10.1038/bjc.1983.63

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  Interferon enhances the excitability of cultured neurones.

Authors:  M C Calvet; I Gresser
Journal:  Nature       Date:  1979-04-05       Impact factor: 49.962

2.  Value of EEG in acute confusional states.

Authors:  R Obrecht; F O Okhomina; D F Scott
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-01       Impact factor: 10.154

3.  p67K kinase in different tissues and plasma of control and interferon-treated mice.

Authors:  B Krust; Y Rivière; A G Hovanessian
Journal:  Virology       Date:  1982-07-15       Impact factor: 3.616

4.  A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion.

Authors:  A Z Rohatiner; F R Balkwill; D B Griffin; J S Malpas; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease.

Authors:  T J Priestman
Journal:  Lancet       Date:  1980-07-19       Impact factor: 79.321

6.  Conventional and spectral EEG analysis in children treated with cytotoxic agents.

Authors:  L Schäffler; P Imbach; A Rüdeberg; F Vassella; K Karbowski
Journal:  Eur J Cancer Clin Oncol       Date:  1982-09
  6 in total
  25 in total

1.  A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.

Authors:  K Sriskandan; P Garner; J Watkinson; K W Pettingale; D Brinkley; F M Calman; D E Tee
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Safety evaluation of biotechnology products.

Authors:  G Zbinden
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

3.  A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.

Authors:  W K Yung; A M Castellanos; P Van Tassel; R P Moser; S G Marcus
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

4.  Cognitive impairment in hepatitis C patients on antiviral therapy.

Authors:  Jessica Irwin; Norah Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

5.  Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities.

Authors:  F Adams; F Fernandez; G Mavligit
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

6.  Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

Authors:  W K Yung; P A Steck; P J Kelleher; R P Moser; M G Rosenblum
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Two cases of influenza B encephalitis.

Authors:  S A Hawkins; J A Lyttle; J H Connolly
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-09       Impact factor: 10.154

Review 8.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

Review 9.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

10.  Human leukocyte alpha interferon-induced transient neurotoxicity in children.

Authors:  J A Katz; D H Mahoney; C P Steuber; D J Fernbach
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.